| Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial GD Demetri, AT van Oosterom, CR Garrett, ME Blackstein, MH Shah, ... The Lancet 368 (9544), 1329-1338, 2006 | 3173 | 2006 |
| Nivolumab in patients with metastatic DNA mismatch repair-deficient or microsatellite instability-high colorectal cancer (CheckMate 142): an open-label, multicentre, phase 2 study MJ Overman, R McDermott, JL Leach, S Lonardi, HJ Lenz, MA Morse, ... The lancet oncology 18 (9), 1182-1191, 2017 | 2527 | 2017 |
| The clinical KRAS (G12C) inhibitor AMG 510 drives anti-tumour immunity J Canon, K Rex, AY Saiki, C Mohr, K Cooke, D Bagal, K Gaida, T Holt, ... Nature 575 (7781), 217-223, 2019 | 1694 | 2019 |
| Circulating tumor DNA analysis detects minimal residual disease and predicts recurrence in patients with stage II colon cancer J Tie, Y Wang, C Tomasetti, L Li, S Springer, I Kinde, N Silliman, M Tacey, ... Science translational medicine 8 (346), 346ra92-346ra92, 2016 | 1364 | 2016 |
| KRASG12C Inhibition with Sotorasib in Advanced Solid Tumors DS Hong, MG Fakih, JH Strickler, J Desai, GA Durm, GI Shapiro, ... New England Journal of Medicine 383 (13), 1207-1217, 2020 | 1284 | 2020 |
| Encorafenib, Binimetinib, and Cetuximab in BRAF V600E–Mutated Colorectal Cancer S Kopetz, A Grothey, R Yaeger, E Van Cutsem, J Desai, T Yoshino, ... New England Journal of Medicine 381 (17), 1632-1643, 2019 | 1228 | 2019 |
| Cardiotoxicity associated with tyrosine kinase inhibitor sunitinib TF Chu, MA Rupnick, R Kerkela, SM Dallabrida, D Zurakowski, L Nguyen, ... The Lancet 370 (9604), 2011-2019, 2007 | 1222 | 2007 |
| Impact of BRAF mutation and microsatellite instability on the pattern of metastatic spread and prognosis in metastatic colorectal cancer B Tran, S Kopetz, J Tie, P Gibbs, ZQ Jiang, CH Lieu, A Agarwal, DM Maru, ... Cancer 117 (20), 4623-4632, 2011 | 824 | 2011 |
| Phase II pilot study of vemurafenib in patients with metastatic BRAF-mutated colorectal cancer S Kopetz, J Desai, E Chan, JR Hecht, PJ O'Dwyer, D Maru, V Morris, ... Journal of clinical oncology 33 (34), 4032, 2015 | 728 | 2015 |
| Circulating tumor DNA as an early marker of therapeutic response in patients with metastatic colorectal cancer J Tie, I Kinde, Y Wang, HL Wong, J Roebert, M Christie, M Tacey, R Wong, ... Annals of Oncology 26 (8), 1715-1722, 2015 | 630 | 2015 |
| Surgical management of advanced gastrointestinal stromal tumors after treatment with targeted systemic therapy using kinase inhibitors CP Raut, M Posner, J Desai, JA Morgan, S George, D Zahrieh, ... Journal of Clinical Oncology 24 (15), 2325-2331, 2006 | 577 | 2006 |
| Metastasis-associated gene expression changes predict poor outcomes in patients with Dukes stage B and C colorectal cancer RN Jorissen, P Gibbs, M Christie, S Prakash, L Lipton, J Desai, D Kerr, ... Clinical Cancer Research 15 (24), 7642-7651, 2009 | 473 | 2009 |
| Hypothyroidism after sunitinib treatment for patients with gastrointestinal stromal tumors J Desai, L Yassa, E Marqusee, S George, MC Frates, MH Chen, ... Annals of internal medicine 145 (9), 660-664, 2006 | 470 | 2006 |
| SMAD2, SMAD3 and SMAD4 mutations in colorectal cancer NI Fleming, RN Jorissen, D Mouradov, M Christie, A Sakthianandeswaren, ... Cancer research 73 (2), 725-735, 2013 | 376 | 2013 |
| PLX4032 in metastatic colorectal cancer patients with mutant BRAF tumors. S Kopetz, J Desai, E Chan, JR Hecht, PJ O'dwyer, RJ Lee, KB Nolop, ... Journal of Clinical Oncology 28 (15_suppl), 3534-3534, 2010 | 356 | 2010 |
| Resistance to BRAF inhibition in BRAF-mutant colon cancer can be overcome with PI3K inhibition or demethylating agents M Mao, F Tian, JM Mariadason, CC Tsao, R Lemos Jr, F Dayyani, ... Clinical cancer research 19 (3), 657-667, 2013 | 332 | 2013 |
| Encorafenib plus cetuximab as a new standard of care for previously treated BRAF V600E–mutant metastatic colorectal cancer: updated survival results and subgroup analyses from … J Tabernero, A Grothey, E Van Cutsem, R Yaeger, H Wasan, T Yoshino, ... Journal of Clinical Oncology 39 (4), 273, 2021 | 328 | 2021 |
| Pexidartinib versus placebo for advanced tenosynovial giant cell tumour (ENLIVEN): a randomised phase 3 trial WD Tap, H Gelderblom, E Palmerini, J Desai, S Bauer, JY Blay, T Alcindor, ... The Lancet 394 (10197), 478-487, 2019 | 321 | 2019 |
| Multicenter retrospective analysis of metastatic colorectal cancer (CRC) with high-level microsatellite instability (MSI-H) J Goldstein, B Tran, J Ensor, P Gibbs, HL Wong, SF Wong, E Vilar, J Tie, ... Annals of Oncology 25 (5), 1032-1038, 2014 | 303 | 2014 |
| Optimizing targeted therapeutic development: Analysis of a colorectal cancer patient population with the BRAFV600E mutation J Tie, P Gibbs, L Lipton, M Christie, RN Jorissen, AW Burgess, M Croxford, ... International journal of cancer 128 (9), 2075-2084, 2011 | 270 | 2011 |
